Achaogen


Needham Shares Two Cents on Achaogen (AKAO) Following Mixed FDA Verdict

It’s a short and dramatic plunge for Achaogen (NASDAQ:AKAO). Today, the drug maker’s shares lost nearly 24% following the news that the FDA …

Cowen Spotlights Opportunity in Achaogen (AKAO) Despite BSI Setback

Cowen’s Chris Shibutani pinpoints enticing commercial prospects ahead for AKAO’s plazomicin.

Needham Remains Bullish on Achaogen (AKAO) Stock Despite FDA AdCom Setback

It’s a short and dramatic plunge for Achaogen (NASDAQ:AKAO). Today, the drug maker’s shares lost 25% of their value following the news that …

Achaogen (AKAO) Shares Plummet 26% Following Disappointing AdCom Vote on BSI; Cowen Shares Insights

Cowen’s Chris Shibutani remains confident on AKAO as he angles for plazomicin’s timely approval in cUTI by the end of June.

Achaogen (AKAO): Will cUTI Asset Impress Today’s AdCom? Cowen Shares Two Cents

Cowen’s Chris Shibutani likes AKAO’s risk-reward set up ahead of today’s AdCom Meeting review of plazomicin.

Watch Out for These Pharmaceutical Players Racing Toward FDA Approvals

Will the FDA writing on the wall bode well for three pharmaceutical firms raring for a PDUFA nod this summer? Achaogen (NASDAQ:AKAO) complicated …